Physician profile
Andrew Kim
NPI 1235572207
$11,212.64
in general payments reported to CMS, 2019-2025
17 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,947 · 2020: $41.97 · 2021: $108 · 2022: $261 · 2023: $265 · 2024: $303 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.91 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $7,283.63 | 2019-2025 | Tremfya |
| Genzyme Corporation | $2,170.01 | 2019 | |
| Biofrontera INC. | $463.44 | 2019 | |
| Abbvie INC. | $260.75 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $218.56 | 2024-2025 | Zoryve |
| Ucb, INC. | $116.80 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $113.53 | 2020-2022 | |
| Epi Health, LLC | $110.33 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $108.06 | 2021 | |
| Allergan, INC. | $97.33 | 2019 | |
| Incyte Corporation | $59.73 | 2024 | Opzelura |
| Leo Pharma INC. | $49.89 | 2024 | Adbry |
| Sanofi-Aventis U.S. LLC | $47.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $45.60 | 2023 | Sotyktu |
| Strata Skin Sciences, INC. | $29.65 | 2025 | Xtrac |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.56 | 2022 | |
| Pfizer INC. | $15.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.